Combinations of FGFR4 inhibitors and bile acid sequestrants
AssigneeNovartis AG
InventorsRobin Alec Fairhurst, Diana Graus Porta, Jacqueline Kinyamu-Akunda, Andreas Joerg Mahl, Luigi Manenti, Andreas Weiss, Armin Wolf, Kuno Wuersch
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.
Claims12
A method of reducing side effects associated with FGFR4 inhibitor therapy, wherein the side effects comprise the increase of
- (a) liver enzyme in the serum, plasma or blood of the subject taking FGFR4 inhibition therapy, wherein the liver enzyme comprises alanine aminotransferase, or
- (b) miRNA122 in the subject taking FGFR4 inhibition therapy,
- wherein the FGFR4 inhibition therapy is for the treatment of liver cancer and the FGFR4 inhibition therapy comprises administration of an FGFR4 inhibitor which comprises N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide;
- and
- a bile acid sequestrant.
A pharmaceutical combination for the treatment of liver cancer comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide in free form or in pharmaceutically acceptable salt form, and a bile acid sequestrant.
A method for reducing side effects associated with FGFR4 inhibition therapy in a subject, the method comprising simultaneously or sequentially administering to the subject cholestyramine and an FGFR4 inhibitor comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide in citric acid salt form.
A method for reducing side effects associated with FGFR4 inhibition therapy in a subject afflicted with liver cancer, the method comprising simultaneously or sequentially administering to the subject an FGFR4 inhibitor for the treatment of liver cancer and a bile acid sequestrant, wherein the side effects comprise the increase of
- (a) liver enzymes in the serum, plasma or blood of the subject taking FGFR4 inhibition therapy, wherein the liver enzyme compromises alanine aminotransferase, or
- (b) miRNA122 in the subject taking FGFR4 inhibition therapy,
- wherein the FGFR4 inhibitor is N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide in free form, in pharmaceutically acceptable salt form or in citric acid form.
Dependencies are inferred from the claim text.